Post the acquisition, Optimus Holding will invest more than 273 million dollars in the next few years for the development of microbial-derived immunotherapeutics against respiratory diseases and inflammation, and other projects. The takeover is also expected to strengthen the company’s biotech cluster in Switzerland.
Read on